Status:
COMPLETED
Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles
Lead Sponsor:
Castle Creek Biosciences, LLC.
Conditions:
Bilateral Nasolabial Fold Wrinkles
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.
Eligibility Criteria
Inclusion
- Subject is at least 18 years of age
- Level of severity of bilateral nasolabial fold wrinkles meeting severity criteria as per protocol
- Level of subject dissatisfaction with both nasolabial fold wrinkles as per protocol
- Ability to comply with the study requirements
- Negative pregnancy test (Females)
- Healthy post-auricular skin for biopsy
Exclusion
- Excessive dermatochalasis of the treatment area
- Inability to lessen the nasolabial fold wrinkles by physically spreading the area apart
- Total area to be treated exceeds 20 cm in length
- Physical attributes which may prevent assessment or treatment as judged by the evaluator
- Use of an investigational product/procedure within 30 days prior to enrollment or plans for use during the study
- Previous treatment with the sponsor's product
- History of active autoimmune disease or organ transplantation
- Diagnosis of cancer, unless successfully treated or in remission (basal cell carcinoma is excluded)
- Active or chronic skin disease
- Known genetic disorders affecting fibroblasts or collagen
- Active systemic infection
- Requires chronic antibiotic or steroidal therapy
- Use of certain commercial products/procedures to the treatment area prior to study enrollment or plans for use during the study
- Use of systemic agents that increase bleeding or clotting, or disorders equated with these effects
- Known allergic reactions to agents used in preparation of treatment
- Excessive exposure to sun without adequate sun protection
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
218 Patients enrolled
Trial Details
Trial ID
NCT00655356
Start Date
November 1 2006
End Date
May 1 2009
Last Update
March 13 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Brighton Medical Corporation
Beverly Hills, California, United States, 91210
2
Therapeutics Clinical Research
San Diego, California, United States, 92123
3
Gwinnett Clinical Research Center
Snellville, Georgia, United States, 30078
4
Dermatology San Antonio
San Antonio, Texas, United States, 78229